Perivascular Stem Cell Composition For Bone

• US 20120244128A1
• Filed: 02/10/2012
• Published: 09/27/2012
• Est. Priority Date: 08/20/2009
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Soo, B. Chia, Ting, Kang, Peault, Bruno
• Granted Patent: US 9,730,965 B2
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Embodiments of the present invention provide an osteogenic composition comprising perivascular stem cells or induced pluripotent cells (iPS) and an osteogenic agent and methods of making and using the same.

Claims

1. A composition, comprising:

a population of perivascular stem cells (PSC) or induced pluripotent stem cells (iPS), and

an osteoinductive agent,

wherein the osteoinductive agent is in a therapeutically effective amount for causing the PSC or iPS to differentiate in the osteoblast lineage or in a therapeutically effective amount for enhancing the survivability or engraftment of the PSC or iPS where PSC or iPS provide trophic factors or enhance vascular ingrowth.

2. The composition of claim 1, wherein the osteoinductive agent is a NELL-1 factor.

3. The composition of claim 1, wherein the PSC or iPS has a density of about 1×

10⁴ to about 1×

10⁸ per 1 mL volume of the composition.

4. The composition of claim 1, wherein the PSC is pericytes or adventitia cells.

5. The composition of claim 1, which is effective for osteoporosis.

6. The composition of claim 1, which is an osteogenic implant.

7. The composition of claim 1, which is an implant for spine fusion.

8. The composition of claim 1, further comprises an excipient.

9. The composition of claim 1, wherein the osteoinductive agent is a NELL-1 factor, and

wherein the composition is an osteogenic scaffold.

19. A method of treating or ameliorating a bone condition, comprising administering to a subject a composition according to claim 1.

20. The method of claim 19, wherein the bone condition is a spine condition or osteoporosis.

10. A method of fabricating a composition for bone regeneration, comprising:

providing an osteoinductive agent,

providing a population of perivascular stem cells (PSC) or induced pluripotent stem cells (iPS), and

forming the composition,

wherein the osteoinductive agent is in a therapeutically effective amount for causing the PSC or iPS to differentiate in the osteoblast lineage or in a therapeutically effective amount for enhancing the survivability or engraftment of the PSC or iPS where PSC or iPS provide trophic factors or enhance vascular ingrowth.

11. The method of claim 10, wherein the osteoinductive agent is a NELL-1 factor.

12. The method of claim 10, wherein the PSC or iPS has a density of about 1×

10⁴ to about 1×

10⁸ per 1 mL volume of the composition.

13. The method of claim 10, wherein the PSC is pericytes or adventitia cells.

14. The method of claim 10, wherein the composition is effective for osteoporosis.

15. The method of claim 10, which is an osteogenic implant.

16. The method of claim 10, which is an implant for spine fusion.

17. The method of claim 10, further comprises an excipient.

18. The method of claim 10, wherein the osteoinductive agent is a NELL-1 factor, and

wherein the composition is an osteogenic scaffold.